Merck Press Releases - EIN Presswire - Press Release Distribution Service

Published on October 1, 2013 - 14:17 GMT

Data from Merck’s Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of data from studies evaluating the company’s investigational oral chronic hepatitis C virus (HCV) treatments …

Distribution channels: Companies

Published on September 23, 2013 - 13:39 GMT

Merck Receives Complete Response Letter for Investigational Medicine Sugammadex Sodium Injection

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission …

Distribution channels: Companies

Published on September 11, 2013 - 08:50 GMT

Merck and AstraZeneca Enter License Agreement for Investigational Oral WEE1 Kinase Inhibitor Therapy for Cancer

WHITEHOUSE STATION, N.J. LONDON--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and AstraZeneca (NYSE: AZN) today announced a worldwide licensing agreement for Merck’s oral small molecule inhibitor of WEE1 kinase (MK …

Distribution channels: Companies

Published on September 9, 2013 - 14:04 GMT

Merck Announces FDA Acceptance of New Drug Application for Investigational Fertility Treatment

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for its investigational fertility treatment, corifollitropin alfa, has been accepted for …

Distribution channels: Companies

Published on July 26, 2013 - 13:31 GMT

Merck Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, issued the following statement regarding the conclusion of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) …

Distribution channels: Companies

Published on July 24, 2013 - 12:32 GMT

Merck Announces FDA Acceptance of New Drug Application for Vorapaxar, Investigational Anti-Thrombotic Medicine

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for its investigational anti-thrombotic medicine, vorapaxar, has been accepted for standard …

Distribution channels: Companies

Published on July 16, 2013 - 17:12 GMT

Merck Statement on FDA Advisory Committee Meeting About Sugammadex Sodium Injection

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, confirmed today that the U.S. Food and Drug Administration (FDA) has cancelled Thursday’s discussion of sugammadex at the Anesthetic and …

Distribution channels: Companies

Published on July 14, 2013 - 12:39 GMT

Merck Presents Findings from Phase 1b Study of Investigational BACE Inhibitor, MK-8931, in Patients with Alzheimer’s Disease

Merck, known as MSD outside the United States and Canada, today announced the presentation of results from a Phase Ib study showing a dose-dependent decrease in β amyloid levels in cerebral spinal fluid (CSF) following administration of MK-8931, Merck’s …

Distribution channels: Companies

Published on July 1, 2013 - 13:13 GMT

Merck Receives Complete Response Letter for Suvorexant, Merck’s Investigational Medicine for Insomnia

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the New …

Distribution channels: Companies

Published on June 2, 2013 - 15:25 GMT

Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in ...

-Merck Expands Lambrolizumab Clinical Development Program- -Study Published Online in the New England Journal of Medicine- Sunday, June 2, 2013 11:15 am EDT "We are very grateful to the patients, investigators, regulators and the broader oncology …

Distribution channels: Companies

Published on May 23, 2013 - 22:02 GMT

Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Merck’s investigational adenosine A2A receptor antagonist for the treatment …

Distribution channels: Companies

Published on May 22, 2013 - 23:21 GMT

Merck Statement on FDA Advisory Committee Meeting for Suvorexant

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided the following statement after the conclusion of the Peripheral and Central Nervous System Drugs Advisory Committee meeting of …

Distribution channels: Companies

Published on May 8, 2013 - 14:14 GMT

Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Biologics License Application (BLA) for its investigational ragweed pollen (Ambrosia artemisiifolia) sublingual …

Distribution channels: Companies

Published on May 7, 2013 - 17:53 GMT

FDA Approves Merck’s LIPTRUZET™ (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved LIPTRUZET™(ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein (LDL) …

Distribution channels: Companies

Published on April 29, 2013 - 12:38 GMT

Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an ...

WHITEHOUSE STATION, N.J. NEW YORK--(BUSINESS WIRE)--Merck Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada (“Merck”), and Pfizer Inc. (NYSE:PFE) today announced that they have entered into a worldwide (except Japan) collaboration …

Distribution channels: Companies

Published on April 24, 2013 - 13:01 GMT

Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the …

Distribution channels: Companies

Published on April 23, 2013 - 10:29 GMT

Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating …

Distribution channels: Companies

Published on April 22, 2013 - 12:32 GMT

Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Evaluating Combination of Investigational ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK) today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination …

Distribution channels: Companies

Published on March 27, 2013 - 13:24 GMT

Merck Announces FDA Acceptance of Biologics License Application for Investigational Grass Pollen Allergy Immunotherapy Tablet

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Biologics License Application (BLA) for its investigational Timothy grass pollen (Phleum pratense) allergy …

Distribution channels: Companies

Published on March 13, 2013 - 12:48 GMT

Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical ...

WHITEHOUSE STATION, N.J. AUSTIN, Texas--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Luminex Corporation (NASDAQ:LMNX) have signed a collaboration and license agreement to develop a companion diagnostic device …

Distribution channels: Companies